L. Torres

Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.

A. Lage, M. Stabin, N. Iznaga-Escobar, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas

A. Casacó, R. Leyva, M. Coca, 2008, Nuclear medicine communications.

BIODISTRIBUTION AND DOSIMETRY OF 99 m Tc-LABELED MONOCLONAL ANTIBODY ior egf / r 3 IN PATIENTS WITH TUMORS OF EPITHELIAL ORIGIN : PRELIMINARY RESULTS

M. Stabin, N. Iznaga-Escobar, M. Ramos, 2022 .

Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer

M. Solano, A. Lage, T. Crombet, 2003, Journal of immunotherapy.

Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma

A. Casacó, R. Leyva, M. Coca, 2008, Cancer biology & therapy.

Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin

T. Crombet, N. Iznaga-Escobar, E. Neninger, 2005, Nuclear medicine communications.

Brain single-photon emission tomography with technetium-99m hexamethylpropylene amine oxime in adolescents with initial-stage schizophrenia

J. Batista, L. Torres, A. Perera, 1995, European Journal of Nuclear Medicine.

99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.

M. Ramos-Suzarte, N. Iznaga-Escobar, R. Pérez, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.